Immunotherapy in Prostate Cancer

Ilya Sobol; R. H. Thompson; Haidong M Dong; Christopher Krco; Eugene D Kwon

doi:10.1007/s11934-015-0509-7

Immunotherapy in Prostate Cancer

Ilya Sobol, R. H. Thompson, Haidong M Dong, Christopher Krco, Eugene D Kwon

Urology

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Immunotherapy for the treatment of malignant neoplasms has made significant progress over the last 20 years. Multiple molecular targets and clinical agents have been developed recently, particularly in the field of metastatic adenocarcinoma of the prostate. Sipuleucel-T is currently the only FDA approved immunotherapy for prostate cancer. PSA-TRICOM (Prostvac) currently has a phase III randomized trial underway after a phase II trial showed an improvement in overall survival. Interestingly, both these agents showed improvement in overall survival with no measurable change in disease state, leading to significant controversy as the utility of these agents in prostate cancer. Ipilimumab revealed a benefit for a sub-cohort of men in a post-docetaxel group and is currently undergoing investigation in a pre-docetaxel group. There are a number of other targets such as PD-1 which have shown effectiveness in other neoplasms that will likely be investigated in the future for use in prostate cancer.

Original language	English (US)
Pages (from-to)	1-5
Number of pages	5
Journal	Current Urology Reports
Volume	16
Issue number	6
DOIs	https://doi.org/10.1007/s11934-015-0509-7
State	Published - Jun 1 2015

Keywords

Immunotherapy
Ipilimumab
Prostate cancer
PSA-TRICOM

ASJC Scopus subject areas

Urology

Access to Document

10.1007/s11934-015-0509-7

Cite this

@article{763530c88ac046aa93a1c665f95e6da8,

title = "Immunotherapy in Prostate Cancer",

abstract = "Immunotherapy for the treatment of malignant neoplasms has made significant progress over the last 20 years. Multiple molecular targets and clinical agents have been developed recently, particularly in the field of metastatic adenocarcinoma of the prostate. Sipuleucel-T is currently the only FDA approved immunotherapy for prostate cancer. PSA-TRICOM (Prostvac) currently has a phase III randomized trial underway after a phase II trial showed an improvement in overall survival. Interestingly, both these agents showed improvement in overall survival with no measurable change in disease state, leading to significant controversy as the utility of these agents in prostate cancer. Ipilimumab revealed a benefit for a sub-cohort of men in a post-docetaxel group and is currently undergoing investigation in a pre-docetaxel group. There are a number of other targets such as PD-1 which have shown effectiveness in other neoplasms that will likely be investigated in the future for use in prostate cancer.",

keywords = "Immunotherapy, Ipilimumab, Prostate cancer, PSA-TRICOM",

author = "Ilya Sobol and Thompson, {R. H.} and Dong, {Haidong M} and Christopher Krco and Kwon, {Eugene D}",

year = "2015",

month = jun,

day = "1",

doi = "10.1007/s11934-015-0509-7",

language = "English (US)",

volume = "16",

pages = "1--5",

journal = "Current Urology Reports",

issn = "1527-2737",

publisher = "Current Science, Inc.",

number = "6",

}

TY - JOUR

T1 - Immunotherapy in Prostate Cancer

AU - Sobol, Ilya

AU - Thompson, R. H.

AU - Dong, Haidong M

AU - Krco, Christopher

AU - Kwon, Eugene D

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Immunotherapy for the treatment of malignant neoplasms has made significant progress over the last 20 years. Multiple molecular targets and clinical agents have been developed recently, particularly in the field of metastatic adenocarcinoma of the prostate. Sipuleucel-T is currently the only FDA approved immunotherapy for prostate cancer. PSA-TRICOM (Prostvac) currently has a phase III randomized trial underway after a phase II trial showed an improvement in overall survival. Interestingly, both these agents showed improvement in overall survival with no measurable change in disease state, leading to significant controversy as the utility of these agents in prostate cancer. Ipilimumab revealed a benefit for a sub-cohort of men in a post-docetaxel group and is currently undergoing investigation in a pre-docetaxel group. There are a number of other targets such as PD-1 which have shown effectiveness in other neoplasms that will likely be investigated in the future for use in prostate cancer.

AB - Immunotherapy for the treatment of malignant neoplasms has made significant progress over the last 20 years. Multiple molecular targets and clinical agents have been developed recently, particularly in the field of metastatic adenocarcinoma of the prostate. Sipuleucel-T is currently the only FDA approved immunotherapy for prostate cancer. PSA-TRICOM (Prostvac) currently has a phase III randomized trial underway after a phase II trial showed an improvement in overall survival. Interestingly, both these agents showed improvement in overall survival with no measurable change in disease state, leading to significant controversy as the utility of these agents in prostate cancer. Ipilimumab revealed a benefit for a sub-cohort of men in a post-docetaxel group and is currently undergoing investigation in a pre-docetaxel group. There are a number of other targets such as PD-1 which have shown effectiveness in other neoplasms that will likely be investigated in the future for use in prostate cancer.

KW - Immunotherapy

KW - Ipilimumab

KW - Prostate cancer

KW - PSA-TRICOM

UR - http://www.scopus.com/inward/record.url?scp=84928402716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928402716&partnerID=8YFLogxK

U2 - 10.1007/s11934-015-0509-7

DO - 10.1007/s11934-015-0509-7

M3 - Article

C2 - 25894495

AN - SCOPUS:84928402716

SN - 1527-2737

VL - 16

SP - 1

EP - 5

JO - Current Urology Reports

JF - Current Urology Reports

IS - 6

ER -

Immunotherapy in Prostate Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this